## Karin E Lundin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3108439/publications.pdf

Version: 2024-02-01

414034 471061 1,061 33 17 32 citations h-index g-index papers 33 33 33 1941 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Oligonucleotide Therapies: The Past and the Present. Human Gene Therapy, 2015, 26, 475-485.	1.4	220
2	Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. Journal of Allergy and Clinical Immunology, 2014, 133, 1410-1419.e13.	1.5	160
3	Biological Activity and Biotechnological Aspects of Peptide Nucleic Acid. Advances in Genetics, 2006, 56, 1-51.	0.8	97
4	Lipidated Peptide Dendrimers Killing Multidrug-Resistant Bacteria. Journal of the American Chemical Society, 2018, 140, 423-432.	6.6	95
5	Biological Activity and Biotechnological Aspects of Locked Nucleic Acids. Advances in Genetics, 2013, 82, 47-107.	0.8	82
6	Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression. Molecular Therapy - Nucleic Acids, 2014, 3, e140.	2.3	28
7	Susceptibility to infections, without concomitant hyper-lgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 ( PGM3 ) gene. Clinical Immunology, 2015, 161, 366-372.	1.4	28
8	LNA effects on DNA binding and conformation: from single strand to duplex and triplex structures. Scientific Reports, 2017, 7, 11043.	1.6	28
9	Formulation and Delivery of Splice-Correction Antisense Oligonucleotides by Amino Acid Modified Polyethylenimine. Molecular Pharmaceutics, 2010, 7, 652-663.	2.3	27
10	Next-generation bis-locked nucleic acids with stacking linker and 2′-glycylamino-LNA show enhanced DNA invasion into supercoiled duplexes. Nucleic Acids Research, 2016, 44, 2007-2019.	6.5	24
11	Nanotechnology approaches for gene transfer. Genetica, 2009, 137, 47-56.	0.5	22
12	Efficient Transfection of siRNA by Peptide Dendrimer–Lipid Conjugates. ChemBioChem, 2016, 17, 2223-2229.	1.3	22
13	Cooperative strand invasion of supercoiled plasmid DNA by mixed linear PNA and PNA–peptide chimeras. New Biotechnology, 2004, 21, 51-59.	2.7	21
14	RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form. Journal of Molecular and Cellular Cardiology, 2015, 82, 186-193.	0.9	19
15	CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. Nucleic Acids Research, 2017, 45, 5153-5169.	6.5	19
16	Stereoselective pH Responsive Peptide Dendrimers for siRNA Transfection. Bioconjugate Chemistry, 2019, 30, 2165-2182.	1.8	19
17	Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored "Bioplex―formation. New Biotechnology, 2005, 22, 185-192.	2.7	17
18	Novel peptide-dendrimer/lipid/oligonucleotide ternary complexes for efficient cellular uptake and improved splice-switching activity. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 132, 29-40.	2.0	17

#	Article	IF	CITATIONS
19	Chemical Development of Therapeutic Oligonucleotides. Methods in Molecular Biology, 2019, 2036, 3-16.	0.4	14
20	Peptide Dendrimer–Lipid Conjugates as DNA and siRNA Transfection Reagents: Role of Charge Distribution Across Generations. Chimia, 2017, 71, 220.	0.3	13
21	Four Novel Splice-Switch Reporter Cell Lines: Distinct Impact of Oligonucleotide Chemistry and Delivery Vector on Biological Activity. Nucleic Acid Therapeutics, 2016, 26, 381-391.	2.0	12
22	Eleven percent intact PGM3 in a severely immunodeficient patient with a novel splice-site mutation, a case report. BMC Pediatrics, 2018, 18, 285.	0.7	10
23	Oligonucleotide–Palladacycle Conjugates as Splice-Correcting Agents. Molecules, 2019, 24, 1180.	1.7	10
24	Sugar and Polymer Excipients Enhance Uptake and Splice-Switching Activity of Peptide-Dendrimer/Lipid/Oligonucleotide Formulations. Pharmaceutics, 2019, 11, 666.	2.0	10
25	Role of Pseudoisocytidine Tautomerization in Triplex-Forming Oligonucleotides: In Silico and in Vitro Studies. ACS Omega, 2017, 2, 2165-2177.	1.6	9
26	Delivery, Effect on Cell Viability, and Plasticity of Modified Aptamer Constructs. Nucleic Acid Therapeutics, 2016, 26, 183-189.	2.0	8
27	The ability of locked nucleic acid oligonucleotides to pre-structure the double helix: A molecular simulation and binding study. PLoS ONE, 2019, 14, e0211651.	1.1	7
28	Oligonucleotide Binding to Non-B-DNA in MYC. Molecules, 2019, 24, 1000.	1.7	5
29	Lipophilic Peptide Dendrimers for Delivery of Splice-Switching Oligonucleotides. Pharmaceutics, 2021, 13, 116.	2.0	5
30	Oligonucleotides Targeting DNA Repeats Downregulate <i>Huntingtin</i> Gene Expression in Huntington's Patient-Derived Neural Model System. Nucleic Acid Therapeutics, 2021, 31, 443-456.	2.0	4
31	2′- <i>O</i> -( <i>N</i> -(Aminoethyl)carbamoyl)methyl Modification Allows for Lower Phosphorothioate Content in Splice-Switching Oligonucleotides with Retained Activity. Nucleic Acid Therapeutics, 2022, ,	2.0	4
32	Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression. Molecular Therapy - Nucleic Acids, 2014, 3, e172.	2.3	3
33	Generation of microglia specific reagents from phage displayed peptide libraries. Journal of Immunological Methods, 2003, 278, 235-247.	0.6	2